Sareum has announced a strategic collaboration with Receptor.AI, a ‘techbio’ company harnessing generative AI to accelerate drug discovery across a range of targets, including TYK2. Sareum had previously reported positive signals from early preclinical testing of six of its TYK2/JAK1 compounds, thr
